首页> 外文期刊>Statistics in medicine >A super-combo-drug test to detect adverse drug events and drug interactions from electronic health records in the era of polypharmacy
【24h】

A super-combo-drug test to detect adverse drug events and drug interactions from electronic health records in the era of polypharmacy

机译:一种超级组合药物测试,以检测多酚疾病时代电子健康记录的不良药物事件和药物相互作用

获取原文
获取原文并翻译 | 示例
       

摘要

Pharmacoinformatics research has experienced a great deal of successes in detecting drug-induced adverse events (AEs) using large-scale health record databases. In the era of polypharmacy, pharmacoinformatics faces many new challenges, and two significant challenges are to detect high-order drug interactions and to handle strongly correlated drugs. In this article, we propose a super-combo-drug test (SupCD-T) to address the aforementioned two challenges. SupCD-T detects drug interactions by identifying optimal drug combinations with increased AE risks. In addition, SupCD-T increases the statistical powers to detect single-drug effects by combining strongly correlated drugs. Although SupCD-T does not distinguish single-drug effects from their combination effects, it is noticeably more powerful in selecting an individual drug effect in the multiple regression analysis, where confounding justification between two correlated drugs reduces the power in testing the individual drug effects on AEs. Our simulation studies demonstrate that SupCD-T has generally better power comparing with the multiple regression analysis. In addition, SupCD-T is able to select meaningful drug combinations (eg, highly coprescribed drugs). Using electronic health record database, we illustrate the utility of SupCD-T and discover a number of drug combinations that have increased risk in myopathy. Some novel drug combinations have not yet been investigated and reported in the pharmacology research.
机译:药物信息学研究经历了使用大规模健康记录数据库检测药物诱导的不良事件(AES)的大量成功。在PolyPharmacy的时代,PharmacoInformatics面临着许多新的挑战,两项重大挑战是检测高阶药物相互作用,并处理强烈相关的药物。在本文中,我们提出了超级组合 - 药物测试(Supcd-T)来解决上述两个挑战。 Supcd-T通过鉴定具有增加的AE风险的最佳药物组合来检测药物相互作用。此外,通过组合强烈相关的药物来增加统计功率以检测单药效应。虽然supcd-t没有区分单药效应从它们的组合效果中,在多元回归分析中选择个体药物效果是显着的,但两个相关药物之间的混淆理由降低了测试各种药物影响的力量AES。我们的仿真研究表明,与多元回归分析相比,SupCD-T具有更好的功率。此外,Supcd-T能够选择有意义的药物组合(例如,高度繁殖的药物)。使用电子健康记录数据库,我们说明了SupCD-T的效用,并发现了许多药物组合,这些药物组合具有增加的肌病风险。在药理学研究中尚未调查和报告一些新的药物组合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号